Furthermore, all-cause mortality and the risk of MI and stroke were lower in group 1 than in group 2, leading the study investigators to suggest that "patients who failed to achieve the therapeutic range after TRT did not see a reduction in MI or stroke." By meta-analyzing these studies [ 35 , 36 , 37 , 40 ], we found that the lack of TRT in otherwise hypogonadal subjects increased their risk of mortality by 30%, although this finding did not reach statistical significance (p=0.07; Fig. 2A ).
1
0.0700
0.0700